Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Taxes (2016 - 2017)

Historic Change in Taxes for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Q3 2017 value amounting to -$2.5 million.

  • Amphastar Pharmaceuticals' Change in Taxes fell 35128.68% to -$2.5 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$5.8 million, marking a year-over-year decrease of 23687.59%. This contributed to the annual value of -$92000.0 for FY2015, which is 11645.8% down from last year.
  • As of Q3 2017, Amphastar Pharmaceuticals' Change in Taxes stood at -$2.5 million, which was down 35128.68% from -$3.2 million recorded in Q2 2017.
  • Amphastar Pharmaceuticals' 5-year Change in Taxes high stood at $6.0 million for Q4 2014, and its period low was -$7.3 million during Q3 2014.
  • For the 5-year period, Amphastar Pharmaceuticals' Change in Taxes averaged around -$314500.0, with its median value being -$85500.0 (2013).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Change in Taxes skyrocketed by 1513750.0% in 2014 and then crashed by 35128.68% in 2017.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Change in Taxes stood at -$40000.0 in 2013, then soared by 15137.5% to $6.0 million in 2014, then plummeted by 83.52% to $991000.0 in 2015, then plummeted by 154.89% to -$544000.0 in 2016, then crashed by 351.29% to -$2.5 million in 2017.
  • Its last three reported values are -$2.5 million in Q3 2017, -$3.2 million for Q2 2017, and $394000.0 during Q1 2017.